MedTrace Logo

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

NCT03104569 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-26

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.

Conditions

  • Cholangitis

Interventions

PROCEDURE

Injection of 37℃ contrast agent

Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent

Sponsors & Collaborators

  • Hepatopancreatobiliary Surgery Institute of Gansu Province

    lead OTHER

Principal Investigators

  • Xun Li, M.D., Ph. D. · Hepatopancreatobiliary Surgery Institute of Gansu Province

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2028-12-01
Completion
2028-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03104569 on ClinicalTrials.gov